Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

The effect of dietary phytosphingosine on cholesterol levels and insulin sensitivity in subjects with the metabolic syndrome

European Journal of Clinical Nutrition volume 64, pages 419–423 (2010)Cite this article

Subjects

Abstract

Background:

Sphingolipids, like phytosphingosine (PS) are part of cellular membranes of yeasts, vegetables and fruits. Addition of PS to the diet decreases serum cholesterol and free fatty acid (FFA) levels in rodents and improves insulin sensitivity.

Objective:

To study the effect of dietary supplementation with PS on cholesterol and glucose metabolism in humans.

Methods:

Twelve men with the metabolic syndrome (MetS) (according to the International Diabetes Federation (IDF) criteria; age 51±2 years (mean±s.e.m.); body mass index (BMI) 32±1 kg/m2) were randomly assigned to 4 weeks of PS (500 mg twice daily) and 4 weeks of placebo (P) in a double-blind cross-over study, with a 4-week wash-out period between both interventions. At the end of each intervention anthropometric measures and serum lipids were measured and an intravenous glucose tolerance test (IVGTT) was performed.

Results:

Phytosphingosine did not affect body weight and fat mass compared with P. PS decreased serum total cholesterol (5.1±0.3 (PS) vs 5.4±0.3 (P) mmol/l; P<0.05) and low-density lipoprotein (LDL)-cholesterol levels (3.1±0.3 (PS) vs 3.4±0.3 (P) mmol/l; P<0.05), whereas it did not alter serum triglyceride and high-density lipoprotein (HDL)-cholesterol levels. In addition, PS lowered fasting plasma glucose levels (6.2±0.3 (PS) vs 6.5±0.3 (P) mmol/l; P<0.05). PS increased the glucose disappearance rate (K-value) by 9.9% during the IVGTT (0.91±0.06 (PS) vs 0.82±0.05 (P) %/min; P<0.05) at similar insulin levels, compared with P, thus implying enhanced insulin sensitivity. PS induced only minor gastrointestinal side effects.

Conclusion:

Dietary supplementation of PS decreases plasma cholesterol levels and enhances insulin sensitivity in men with the MetS.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Alberti KG, Zimmet P, Shaw J (2006). Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23, 469–480.

    Article  CAS  Google Scholar 

  • Barrenetxe J, Aranguren P, Grijalba A, Martinez-Penuela JM, Marzo F, Urdaneta E (2006). Effect of dietary quercetin and sphingomyelin on intestinal nutrient absorption and animal growth. Br J Nutr 95, 455–461.

    Article  CAS  Google Scholar 

  • Berra B, Colombo I, Sottocornola E, Giacosa A (2002). Dietary sphingolipids in colorectal cancer prevention. Eur J Cancer Prev 11, 193–197.

    Article  CAS  Google Scholar 

  • Duivenvoorden I, Voshol PJ, Rensen PC, van Duyvenvoorde W, Romijn JA, Emeis JJ et al. (2006). Dietary sphingolipids lower plasma cholesterol and triacylglycerol and prevent liver steatosis in APOE*3Leiden mice. Am J Clin Nutr 84, 312–321.

    Article  CAS  Google Scholar 

  • Ford ES (2005). Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28, 1769–1778.

    Article  Google Scholar 

  • Ford ES, Giles WH, Dietz WH (2002). Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287, 356–359.

    Article  Google Scholar 

  • Harder T, Simons K (1997). Caveolae, DIGs, and the dynamics of sphingolipid-cholesterol microdomains. Curr Opin Cell Biol 9, 534–542.

    Article  CAS  Google Scholar 

  • Hendriks HF, Brink EJ, Meijer GW, Princen HM, Ntanios FY (2003). Safety of long-term consumption of plant sterol esters-enriched spread. Eur J Clin Nutr 57, 681–692.

    Article  CAS  Google Scholar 

  • Hendriks HF, Weststrate JA, van Vliet T, Meijer GW (1999). Spreads enriched with three different levels of vegetable oil sterols and the degree of cholesterol lowering in normocholesterolaemic and mildly hypercholesterolaemic subjects. Eur J Clin Nutr 53, 319–327.

    Article  CAS  Google Scholar 

  • Imaizumi K, Tominaga A, Sato M, Sugano M (1992). Effects of dietary sphingolipids on levels of serum and liver lipids in rats. Nutr Res 12, 543–548.

    Article  CAS  Google Scholar 

  • Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M et al. (2001). Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24, 683–689.

    Article  CAS  Google Scholar 

  • Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C et al. (2004). Acarbose attenuates experimental non-alcoholic steatohepatitis. Biochem Biophys Res Commun 315, 699–703.

    Article  CAS  Google Scholar 

  • Lundback K (1962). Intravenous glucose tolerance as a tool in definition and diagnosis of diabetes mellitus. Br Med J 1, 1507–1513.

    Article  Google Scholar 

  • Merrill Jr AH, Schmelz EM, Dillehay DL, Spiegel S, Shayman JA, Schroeder JJ et al. (1997). Sphingolipids—the enigmatic lipid class: biochemistry, physiology, and pathophysiology. Toxicol Appl Pharmacol 142, 208–225.

    Article  CAS  Google Scholar 

  • Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E (1995). Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 333, 1308–1312.

    Article  CAS  Google Scholar 

  • Noh SK, Koo SI (2004). Milk sphingomyelin is more effective than egg sphingomyelin in inhibiting intestinal absorption of cholesterol and fat in rats. J Nutr 134, 2611–2616.

    Article  CAS  Google Scholar 

  • Okada K, Yanagawa T, Warabi E, Yamastu K, Uwayama J, Takeda K et al. (2009). The alpha-glucosidase inhibitor acarbose prevents obesity and simple steatosis in sequestosome 1/A170/p62 deficient mice. Hepatol Res 39, 490–500.

    Article  CAS  Google Scholar 

  • Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI (2005). Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54, 603–608.

    Article  CAS  Google Scholar 

  • Ravikumar B, Gerrard J, Dalla MC, Firbank MJ, Lane A, English PT et al. (2008). Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content. Diabetes 57, 2288–2295.

    Article  CAS  Google Scholar 

  • Schmelz EM, Crall KJ, Larocque R, Dillehay DL, Merrill Jr AH (1994). Uptake and metabolism of sphingolipids in isolated intestinal loops of mice. J Nutr 124, 702–712.

    Article  CAS  Google Scholar 

  • Segal P, Eliahou HE, Petzinna D, Neuser D, Bruckner A, Spengler M (2005). Long-term efficacy and tolerability of acarbose treatment in patients with type 2 diabetes mellitus. Clin Drug Investig 25, 589–595.

    Article  CAS  Google Scholar 

  • Tang JL, Armitage JM, Lancaster T, Silagy CA, Fowler GH, Neil HA (1998). Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ 316, 1213–1220.

    Article  CAS  Google Scholar 

  • Vesper H, Schmelz EM, Nikolova-Karakashian MN, Dillehay DL, Lynch DV, Merrill Jr AH (1999). Sphingolipids in food and the emerging importance of sphingolipids to nutrition. J Nutr 129, 1239–1250.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands

    M Snel, M A Sleddering, L M Havekes & I M Jazet

  2. Department of Endocrinology & Metabolism, Leiden University Medical Center, Leiden, The Netherlands

    H Pijl, L M Havekes & J A Romijn

  3. TNO Quality of Life, Zeist, The Netherlands

    W F Nieuwenhuizen

  4. Department of Clinical Chemistry, Leiden University Medical Center, Leiden, The Netherlands

    M Frölich

  5. Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands

    L M Havekes

  6. TNO Quality of Life, Leiden, The Netherlands

    L M Havekes

Authors
  1. M Snel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M A Sleddering
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Pijl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W F Nieuwenhuizen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Frölich
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L M Havekes
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J A Romijn
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. I M Jazet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Snel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Snel, M., Sleddering, M., Pijl, H. et al. The effect of dietary phytosphingosine on cholesterol levels and insulin sensitivity in subjects with the metabolic syndrome. Eur J Clin Nutr 64, 419–423 (2010). https://doi.org/10.1038/ejcn.2009.154

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ejcn.2009.154

Keywords

Search

Advanced search

Quick links